Why is Novo Nordisk suing Eli Lilly over GLP‑1 drugs and what does it mean for Medicare pricing?

Novo Nordisk filed a lawsuit against Eli Lilly concerning competition around GLP‑1 medicines, a class that has become central to diabetes and weight‑loss therapy. The dispute could shape how Medicare price‑setting and patent exclusivity are handled, influencing formulary negotiations and future GLP‑1 development strategies.